Effects of the Angiotensin II Receptor Blockers Telmisartan vs Valsartan in Combination With Hydrochlorothiazide 25 mg Once Daily for the Treatment of Hypertension
Open Access
- 1 September 2006
- journal article
- research article
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 8 (9) , 626-633
Abstract
To attain recent goals of blood pressure (BP) control, multiple drug therapy combinations are required, including higher doses of thiazide diuretics in combination with other classes of antihypertensive drug therapy. Thus, the authors evaluated the antihypertensive effects of telmisartan vs valsartan when combined with hydrochlorothiazide (HCTZ) 25 mg in a large (N=1066), placebo‐controlled trial in patients with stage 1 or 2 hypertension. The primary end points were the changes from baseline in seated diastolic and systolic BP at the end of the 8‐week treatment period. Safety end points included adverse events, changes in laboratory parameters, and pulse rate. Changes from baseline in BP following telmisartan‐HCTZ (−24.0/−17.6 mm Hg) were significantly greater than both placebo (−4.4/−6.8 mm Hg) and valsartan‐HCTZ (−21.2/−16.1 mm Hg) (vs placebo, P<.001 for systolic and diastolic BP; vs valsartan‐HCTZ, P=.004 for systolic BP and P=.019 for diastolic BP). The total number of patients with at least 1 adverse event reported were similar among the 3 treatment groups (placebo, 49%; telmisartan‐HCTZ, 43%; and valsartan‐HCTZ, 38%). In conclusion, telmisartan‐HCTZ at doses of 80/25 mg lowered both systolic and diastolic BP to a greater extent than valsartan‐HCTZ at doses of 160/25 mg. These data support using a higher dose of a thiazide diuretic (25 mg) with a long‐acting angiotensin receptor blocker as a useful strategy for improving hypertension control.Keywords
This publication has 22 references indexed in Scilit:
- Fixed-Dose Combinations in the Management of HypertensionAmerican Journal of Cardiovascular Drugs, 2005
- Sustained antihypertensive activity of telmisartan compared with valsartanBlood Pressure Monitoring, 2004
- Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension—a randomised ABPM studyJournal of Human Hypertension, 2003
- 2003 European Society of Hypertension???European Society of Cardiology guidelines for the management of arterial hypertension*Journal Of Hypertension, 2003
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Candesartan Cilexetil plus Hydrochlorothiazide CombinationDrugs, 2002
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study IIJournal of Human Hypertension, 2001